Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo- RAS -Wildtype Metastatic Colorectal Cancer Is Transient.
Florence T H WuJames T TophamChris J O'CallaghanHarriet E FeilotterHagen F KenneckeLeylah DrusboskyDaniel J RenoufDerek J JonkerDongsheng TuEric X ChenJonathan M LoreePublished in: JCO precision oncology (2024)
-WT phenomenon in the CO.26 trial. However, 67% of apparent cases were transient with subsequent re-emergence.